Devanesan Arul Ananth1, Angappan Rameshkumar2, Ramachandran Jeyadevi1, G Smilin Bell Aseervatham1, Jaganathan Sripriya3, Prabaharan Chandra Bose4, Thilagar Sivasudha5. 1. Department of Environmental Biotechnology, Bharathidasan University, Tiruchirappalli 620 024, Tamil Nadu, India. 2. Department of Environmental Biotechnology, Bharathidasan University, Tiruchirappalli 620 024, Tamil Nadu, India; TUV-SUD, South Asia Laboratory, Bangalore, 560 058, India. 3. SRM Research Institute, SRM University, Kattankulathur, Chennai 603 203, Tamil Nadu, India. 4. Department of Biotechnology, Anna University, Tiruchirappalli, 620 024 Tamil Nadu, India. 5. Department of Environmental Biotechnology, Bharathidasan University, Tiruchirappalli 620 024, Tamil Nadu, India. Electronic address: sudacoli@yahoo.com.
Abstract
PURPOSE: Pergularia daemia Forsk. (Asclepiadaceae) is a traditionally reported medicinal herb used to treat joint pain and arthritis. However, there are no scientific reports about anti-arthritic activity of P. daemia methanolic extract on rats as animal model. This study identifies bioactive compounds present in the P. daemia methanolic extract and evaluates its anti-arthritic potential in CFA induced arthritic rats. METHODS AND RESULTS: Phytoconstituents of P. daemia extract were examined using LC-ESI/MS method. Anti-arthritic activity of P. daemia extract was determined by various biochemical experiments (RF, ESR and CRP), ultrasonography and histological analysis. LC-ESI/MS analysis resulted in the identification of major flavonoids compounds such as formononetin, qurecetin, chrysoeriol, taxifolin and naringenin. Serum biomarker analysis, after the treatment with PDME (500mg/kg b.w.) revealed that the hemoglobin (11.84±0.42g/dL) and RBC (8.38±0.67million/mm(3)) levels were significantly increased whereas WBC (8.91±0.38thousands/mm(3)), RF (17.94±0.45IU/mL), ESR (7.91±0.12mm/h) and CRP (22.56±0.26mg/L) levels were decreased when compared with the CFA induced arthritic control group. Histology results revealed that treatment with PDME has resulted in significant prevention against bony destruction by decreasing soft tissue swelling and narrowing of joint spaces (250 and 500mg/kg b.w.). CONCLUSION: Anti-arthritic effect of P. daemia might be due to the presence of these bioactive flavonoids. These findings lend pharmacological support to the reported folkloric use of P. daemia in the treatment and management of painful, arthritic inflammatory conditions.
PURPOSE: Pergularia daemia Forsk. (Asclepiadaceae) is a traditionally reported medicinal herb used to treat joint pain and arthritis. However, there are no scientific reports about anti-arthritic activity of P. daemiamethanolic extract on rats as animal model. This study identifies bioactive compounds present in the P. daemiamethanolic extract and evaluates its anti-arthritic potential in CFA induced arthritic rats. METHODS AND RESULTS: Phytoconstituents of P. daemia extract were examined using LC-ESI/MS method. Anti-arthritic activity of P. daemia extract was determined by various biochemical experiments (RF, ESR and CRP), ultrasonography and histological analysis. LC-ESI/MS analysis resulted in the identification of major flavonoids compounds such as formononetin, qurecetin, chrysoeriol, taxifolin and naringenin. Serum biomarker analysis, after the treatment with PDME (500mg/kg b.w.) revealed that the hemoglobin (11.84±0.42g/dL) and RBC (8.38±0.67million/mm(3)) levels were significantly increased whereas WBC (8.91±0.38thousands/mm(3)), RF (17.94±0.45IU/mL), ESR (7.91±0.12mm/h) and CRP (22.56±0.26mg/L) levels were decreased when compared with the CFA induced arthritic control group. Histology results revealed that treatment with PDME has resulted in significant prevention against bony destruction by decreasing soft tissue swelling and narrowing of joint spaces (250 and 500mg/kg b.w.). CONCLUSION: Anti-arthritic effect of P. daemia might be due to the presence of these bioactive flavonoids. These findings lend pharmacological support to the reported folkloric use of P. daemia in the treatment and management of painful, arthritic inflammatory conditions.
Authors: Allan J C Bussmann; Sergio M Borghi; Tiago H Zaninelli; Telma S Dos Santos; Carla F S Guazelli; Victor Fattori; Talita P Domiciano; Felipe A Pinho-Ribeiro; Kenji W Ruiz-Miyazawa; Antonio M B Casella; Josiane A Vignoli; Doumit Camilios-Neto; Rubia Casagrande; Waldiceu A Verri Journal: Inflammopharmacology Date: 2019-01-05 Impact factor: 4.473